Second Sight Medical Products reported a net loss of $8 million, or $0.12 per share, in 2018’s second quarter compared with a net loss of $6.8 million, or $0.12 per share, in the same time period during 2017, according to a press release.
Net sales totaled $1.9 million in the quarter compared with $2.2 million a year ago.
General and administrative expenses decreased from $2.9 million in 2017’s second quarter to $2.6 million in 2018, which the company attributed to lower stock-based compensation charges.
Selling and marketing expenses and clinical and regulatory expenses both increased slightly from $2.4 million to $2.9 million and from $0.7 million to $1.1 million, respectively. Research and development costs went up to $2.4 million from $1.9 million.